Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria

References

• BrozekJLBousquetJBaena-CagnaniCEGlobal Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working GroupAllergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revisionJ Allergy Clin Immunol2010126346647620816182
   PubMed Web of Science ®Google Scholar
• CorcósteguiRLabeagaLInnerárityABerisaAOrjalesAPreclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activityDrugs R D20056637138416274260
   PubMedGoogle Scholar
• García-GeaCMartínez-ColomerJAntonijoanRMValienteRBarbanojMJComparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatmentsJ Clin Psychopharmacol200828667568519011437
   PubMed Web of Science ®Google Scholar
• CorcósteguiRLabeagaLInnerárityABerisaAOrjalesAIn vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonistDrugs R D20067421923116784247
   PubMedGoogle Scholar
• Alvarez-MonMSan AntonioELuceroMSanzELedoFDe la HeraABilastine, a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytesAllergy200964Suppl 90555
   Google Scholar
• SologurenAValienteRCreanCMcLavertyDRelationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. 36th Annual Meeting of the American College of Clinical Pharmacology; September 9–11, 2007; San Francisco, USAJ Clin Pharmacol20074791198 Abstract 69.
   Web of Science ®Google Scholar
• JauregizarNde la FuenteLLuceroMLSologurenALealNRodríguezMPharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastineClin Pharmacokinet200948854355419705924
   PubMed Web of Science ®Google Scholar
• CreanCRoupeKSologurenAValienteRThe pharmacokinetics of bilastine after single and 14 days once daily administration. 8th Congress of the European Association of Clinical Pharmacology and Therapeutics; August 29–September 1, 2007; Amsterdam, The NetherlandsBasic Clin Pharmacol Toxicol.2007101Suppl 1148 Abstract P252.
   Google Scholar
• BaileyDGFruit juice inhibition of uptake transport: a new type of food-drug interactionBr J Clin Pharmacol20107064565521039758
   PubMed Web of Science ®Google Scholar
• Bilastine SPCTexto propuesto para la ficha técnica Bilastina 20 mg [Summary of Product Characteristics for Bilastine 20 mg.] Available from: http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=73027&formato=pdf&formulario=FICHAS&file=ficha.pdf. Accessed February 20, 2013. Spanish.
   Google Scholar
• CreanCValienteRSologurenAMcLavertyDEffect of grapefruit juice on the pharmacokinetics of bilastine. 36th Annual Meeting of the American College of Clinical Pharmacology; September 9–11, 2007; San Francisco, USAJ Clin Pharmacol20074791198 Abstract 71.
   Web of Science ®Google Scholar
• MumfordRAllanLHoeyRThe disposition, metabolism and elimination in rats of bilastine, a potent, selective H1 receptor antagonist. 8th International ISSX Meeting; October 9–12, 2007; Sendai, JapanDrug Metab Rev.200739Suppl I200201 Abstract 282.
   Google Scholar
• SologurenALuceroMLValienteRValienteRCharlesHMairSJHuman mass balance with [14C]-bilastine following oral administration to healthy volunteers. 9th Congress of the European Association for Clinical Pharmacology and Therapeutics; July 12–15, 2009, Edinburgh, UKBasic Clin Pharmacol Toxicol.2009105Suppl 1106107 Abstract TP85.
   Google Scholar
• CreanCSologurenAValienteRMcLavertyDThe drug-drug interaction of ketoconazole on bilastine pharmacokinetics. 8th Congress of the European Association of Clinical Pharmacology and Therapeutics; August 29–September 1, 2007; Amsterdam, The NetherlandsBasic Clin Pharmacol Toxicol.2007101Suppl 1148149 Abstract P253.
   Google Scholar
• RodríguezMLuceroMLOrjalesAGonzaloALealNCalvoREstimation of bilastine dose in paediatrics. IX World Conference on Clinical Pharmacology Therapeutics; July 27–August 1, 2008; Quebec City, CanadaCan J Clin Pharmacol.2008153e680 Abstract 554.
   Google Scholar
• BousquetJAnsóteguiICanonicaGWEstablishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence reviewCurr Med Res Opin201228113113922149770
   PubMed Web of Science ®Google Scholar
• TakanoMHasegawaRFukudaTYumotoRNagaiJMurakamiTInteraction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cellsEur J Pharmacol199835832892949822896
   PubMed Web of Science ®Google Scholar
• BachertCKunaPZuberbierTBilastine in allergic rhinoconjunctivitis and urticariaAllergy201065Suppl 93S1S13
   Web of Science ®Google Scholar
• García-GeaCClosSAntonijoanRMGichIValienteRBarbanojMJCrossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. 20th Congress of the Spanish Clinical Pharmacology Society; October 29–November 2, 2006; Tenerife, SpainBasic Clin Pharmacol Toxicol.200699Suppl I30 Abstract EC13.
   Google Scholar
• HorakFZieglmayerPZieglmayerRLemellPThe effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge ChamberInflamm Res201059539139819943178
   PubMed Web of Science ®Google Scholar
• CruchMKComparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare response in humansInflamm Res201160121107111221874559
   PubMed Web of Science ®Google Scholar
• BousquetJKhaltaevNCruzAAAllergic Rhinitis and its Impact on Asthma (ARIA) 2008 updateAllergy20086386816018331513
   PubMed Web of Science ®Google Scholar
• DávilaISastreJMullolJEffect of bilastine upon nasal obstructionJ Investig Allergol Clin Immunol201121Suppl 328
   PubMed Web of Science ®Google Scholar
• JuniperEFRohrbaughTMeltzerEOA questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitisJ Allergy Clin Immunol2003111348449012642826
   PubMed Web of Science ®Google Scholar
• WoodsLCraigTJThe importance of rhinitis on sleep, daytime somnolence, productivity and fatigueCurr Opin Pulm Med200612639039617053486
   PubMed Web of Science ®Google Scholar
• GelfandEWInflammatory mediators in allergic rhinitisJ Allergy Clin Immunol2004114Suppl 5S135S13815536444
   PubMed Web of Science ®Google Scholar
• WangDSmitzJWaterschootSClementPAn approach to the understanding of the nasal early-phase reaction induced by nasal allergen challengeAllergy19975221621679105520
   PubMed Web of Science ®Google Scholar
• SchroederJTSchleimerRPLichtensteinLMKreutnerWInhibition of cytokine generation and mediator release by human basophils treated with desloratadineClin Exp Allergy20013191369137711591186
   PubMed Web of Science ®Google Scholar
• BachertCKunaPSanquerFBilastine International Workin GroupComparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patientsAllergy200964115816519132976
   PubMed Web of Science ®Google Scholar
• KunaPBachertCNowackiZBilastine International Working GroupEfficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group studyClin Exp Allergy20093991338134719438584
   PubMed Web of Science ®Google Scholar
• SastreJMullolJValeroAValienteRBilastine Study GroupEfficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitisCurr Med Res Opin201228112113022077106
   PubMed Web of Science ®Google Scholar
• BartraJMullolJMontoroJEffect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitisJ Investig Allergol Clin Immunol201121Suppl 32433
   PubMed Web of Science ®Google Scholar
• JáureguiIBartraJdel CuvilloABilastine and quality of lifeJ Investig Allergol Clin Immunol201121Suppl 31623
   PubMedGoogle Scholar
• KaplanAPChronic urticaria: pathogenesis and treatmentJ Allergy Clin Immunol2004114346547415356542
   PubMed Web of Science ®Google Scholar
• ZuberbierTAseroRBindslev-JensenCDermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy OrganizationEAACI/GA(2)LEN/EDF/WAO guideline: management of urticariaAllergy200964101427144319772513
   PubMed Web of Science ®Google Scholar
• FerrerMSastreJJáureguiIEffect of antihistamine up-dosing in chronic urticariaJ Investig Allergol Clin Immunol201121Suppl 33439
   PubMed Web of Science ®Google Scholar
• ZuberbierTOantaABogackaEBilastine International Working GroupComparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled studyAllergy201065451652819860762
   PubMed Web of Science ®Google Scholar
• ArtecheJKLedoFCasadesusABilastine. Preclinical toxicology review. XII International Congress of Toxicology; July 19–23, 2010; Barcelona, SpainToxicol Lett.2010196SupplS256 Abstract P302-026.
   Web of Science ®Google Scholar
• SommerEWeberKLuceroMLArtecheJKOrjalesAOncogenicity risk assessment of bilastine, a novel antihistamine compound. 45th Congress of the European Societies of Toxicology (Eurotox); October 5–8, 2008; Rothes, GreeceToxicol Lett.2008180SupplS156 Abstract P20.
   Web of Science ®Google Scholar
• CarterNJBilastine: in allergic rhinitis and urticariaDrugs20127291257126922686617
   PubMed Web of Science ®Google Scholar
• GraffCStruijkJJKantersJKAndersenMPToftETylBEffects of bilastine on T-wave morphology and the QTc interval. A randomized, double-blind, placebo-controlled, thorough QTc studyClin Drug Investig2012325339351
   PubMed Web of Science ®Google Scholar
• TylBKabbajMAzzamSLack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysisJ Clin Pharmacol201252689390321642470
   PubMed Web of Science ®Google Scholar
• RichardsonGSRoehrsTARosenthalLKoshorekGRothTTolerance to daytime sedative effects of H1 antihistaminesJ Clin Psychopharmacol200222551151512352276
   PubMed Web of Science ®Google Scholar
• ConenSTheunissenELVan OersACValienteRRamaekersJGAcute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteersJ Psychopharmacol201125111517153320855350
   PubMed Web of Science ®Google Scholar
• MontoroJMullolJDaáilaIBilastine and the central nervous systemJ Investig Allergol Clin Immunol201121Suppl 3915
   PubMed Web of Science ®Google Scholar